Michael Esq - TG Therapeutics CEO Chairman
| TGTX Stock | USD 34.55 3.40 10.91% |
Insider
Michael Esq is CEO Chairman of TG Therapeutics
| Age | 58 |
| Address | 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 |
| Phone | 212 554 4484 |
| Web | https://www.tgtherapeutics.com |
TG Therapeutics Management Efficiency
At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.07 in 2024. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 333.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 7.5 M in 2024. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
Management Performance
| Return On Equity | -0.0805 | ||||
| Return On Asset | -7.0E-4 |
TG Therapeutics Leadership Team
Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Corp CFO | ||
| Jenna Bosco, Director of Investor Relations | ||
| Adam Waldman, Chief Commercial Officer | ||
| Sean CPA, Corporate CFO | ||
| Michael Esq, CEO Chairman |
TGTX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TG Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0805 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 4.76 B | ||||
| Shares Outstanding | 155.66 M | ||||
| Shares Owned By Insiders | 9.50 % | ||||
| Shares Owned By Institutions | 66.32 % | ||||
| Number Of Shares Shorted | 32 M | ||||
| Price To Earning | (4.14) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.